Article
Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer.
Oncotarget - 20 Feb 2015
Fujita Yu, Yagishita Shigehiro, Takeshita Fumitaka, Yamamoto Yusuke, Kuwano Kazuyoshi, Ochiya Takahiro
Abstract excerpt
RNA interference (RNAi) is a powerful gene-silencing platform for cancer treatment. Previously, we demonstrated that ribophorin II (RPN2), which is part of the N-oligosaccharyl transferase complex, regulates docetaxel sensitivity and tumor lethal phenotypes in breast cancer. However, the molecular functions and clinical relevance of RPN2 in non-small-cell lung cancer (NSCLC) remain unknown. Here, we examined RPN2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.